HFS
VIVO

Hantz Financial Services’s Meridian Bioscience Inc VIVO Stock Holding History

Hantz Financial Services’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-400
Closed -$9K – 877
2021
Q2 		$9K Buy
+400
New +$8.48K ﹤0.01% 701

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Hantz Financial Services's VIVO Position: Q3 2021 in Review

Hantz Financial Services sold out of Meridian Bioscience Inc (VIVO) in Q3 2021, closing a stake of 400 shares — an estimated $9K sold.

Hantz Financial Services first reported a position in VIVO in Q2 2021 and held it in 1 quarter. The position peaked at $9K in Q2 2021. 180 funds tracked by Wall St. Rank hold VIVO as of Q3 2021.

  • Hantz Financial Services reported no remaining Meridian Bioscience Inc position as of Q3 2021 after selling out during the quarter.
  • Hantz Financial Services sold 400 Meridian Bioscience Inc shares in Q3 2021, an estimated $9K.
  • Hantz Financial Services first reported a position in Meridian Bioscience Inc in Q2 2021 and held it in 1 quarter.
  • Hantz Financial Services's Meridian Bioscience Inc position peaked at $9K in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2021.

Based on Hantz Financial Services's 13F filing for Q3 2021, filed 1 Sep 2022.